University Of California Los Angeles
October 12, 2021In 2017, Jeffrey Bazarian, M.D., M.P.H., a concussion researcher at the University of Rochester Medical Center, wanted to pull together a national network of concussion clinics to run multi-site clinical trials. He turned to the University of Rochester Clinical and Translational Science Institute (UR CTSI) and Trial Innovation Network (TIN) for help and ended up connecting with a group already
-University Of California Los AngelesDr. Hwang is an Attending Radiologist within the Division of Body Imaging, Director of Neonatal Imaging, and an Assistant Professor of Radiology at the University of Pennsylvania. Her KL2 project is on the validation of quantitative brain contrast enhanced ultrasound for evaluation of brain health in porcine model and infants of brain injury. Required registration at https://uclahs.fyi/Hwang to
-University Of California Los AngelesDr. Steven Hicks, MD, PhD is an Associate Professor of Pediatrics at Penn State University. His translational research identifies molecular biomarkers that inform child growth, neurodevelopment and disease. ABSTRACT: Mild traumatic brain injury (mTBI) is extremely common among adolescents, who suffer disproportionately from prolonged concussion symptoms - a condition for which no biologic test
Urea cycle disorders (UCDs) are rare but devastating genetic conditions. In 2003, the Urea Cycle Disorders Consortium (UCDC) became one of the first members of the RDCRN. Since then, UCDC has flourished into an international network of 16 academic centers in the United States, Canada and Europe that provide state-of-the-art care and conduct cutting-edge clinical research. The UCDC is currently
The Primary Immune Deficiency Treatment Consortium (PIDTC) was established in 2009 to study and define optimal treatments for rare genetic disorders of the immune system, collectively known as primary immunodeficiency diseases. The PIDTC includes 44 immunology and transplantation centers throughout the United States and Canada as well as six patient advocacy groups. In its first nine years, the
Dystonia syndromes are disorders that cause certain regions of the body to have uncontrollable movements, including twisting, spasms, repetitive shaking, or jerking. The most common dystonia disorders affect the head and neck, eyelids, vocal cords, hands, forearms, and sometimes the entire body. The overall goal of the Dystonia Coalition is to accelerate progress in dystonia research. Specific
The Brain Vascular Malformation Consortium (BVMC) focuses on three rare brain conditions: familial cerebral cavernous malformation (CCM), Sturge-Weber syndrome (SWS), and hereditary hemorrhagic telangiectasia (HHT). These disorders are poorly understood, costly to manage, and can cause serious complications such as hemorrhages, seizures, and problems with spinal cord, nerve or brain function. Over
Brittle bone disorders (BBDs), also known as osteogenesis imperfecta, include 13 inherited conditions involving bones that break easily. Brittle bone disorders can cause deformity and chronic pain and lead to premature death. The Brittle Bone Disorders Consortium (BBDC) includes ten medical research sites working to better understand and treat these disorders. The consortium aims to explore the
University Of California Los AngelesRecognizing the diversity of populations within California and the disproportionate burden of COVID-19 on minority and low income communities, we have formed a statewide community-partnered collaborative funded by the NIH/NHLBI to address disparities in COVID-19 knowledge, awareness, and communication; vaccine trial participation; and vaccine hesitancy and accessibility. The statewide
Autism spectrum disorder (ASD) affects 1 in 59 children in the United States and is a major public health concern and challenge. The Developmental Synaptopathies Consortium (DSC) aims to explore the underlying causes of autism by focusing on three rare genetic disorders related to ASD, including Tuberous Sclerosis Complex (TSC), PTEN Hamartoma Tumor Syndrome (PHTS) and Phelan-McDermid Syndrome
July 21, 2020One of the first synergy papers supported by the CLIC and CTSA consortium was published in the Journal of Clinical and Translational Science. Abstract: A primary barrier to translation of clinical research discoveries into care delivery and population health is the lack of sustainable infrastructure bringing researchers, policymakers, practitioners, and communities together to reduce silos in
The Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) is a clinical trials network funded by the National Institute for Neurological Disorders and Stroke (NINDS), the National Heart Lung and Blood Institute (NHLBI) and the National Center for Advancing Translational Science (NCATS). The goal of the SIREN Network is to improve the outcomes of patients with neurologic, cardiac
UC BRAID, or University of California Biomedical Research Acceleration, Integration, and Development, is a network of five UC campuses - Davis, Irvine, Los Angeles, San Diego and San Francisco. Formed in 2010, the UC BRAID consortium aims to accelerate research and improve health through collaboration, sharing resources, and infrastructure development. We connect researchers and administrators to
February 14, 2020Celebrating ten years of shared infrastructure and programs that accelerate research and improve health, UC BRAID convened its annual meeting on October 14-15, 2019 at the UCLA Luskin Conference Center. UC BRAID, the University of California Biomedical Research Acceleration, Integration, & Development, is a consortium of the five UC academic medical centers—Davis, Irvine, Los Angeles, San Diego
The Greater Los Angeles CTSA Consortium was established to leverage our local talents in collaborations that benefit both our local communities and our approaches to clinical research. The two main activities that are currently underway are (a) a Community Engagement working group that is developing and evaluating an intervention with promotoras to increase Latino representation in clinical trials
-University Of California Los AngelesPlease join us for the inaugural California Precision Health Summit Feb. 6-7 at UCLA. The summit will focus on cancer: tumor evolution, liquid biopsies, and immuno-oncology. Featured speakers include: - Christina Curtis, PhD, MSc - Caroline Dive, CBE - Antoni Ribas, MD, PhD - Charles Swanton, FRS, FMedSci, FRCP - Peter Van Loo, PhD Register online by Dec. 14
November 01, 2019UCLA's David Shackelford and colleagues have identified a new biomarker that could indicate how likely someone is to respond to treatment for lung cancer. In a test using mice, the scientists found that the level of activity of the mitochondria in lung tumor cells could potentially predict who would respond favorably to a type of drug called a complex I inhibitor, which targets mitochondrial
University Of California Los AngelesUCLA CTSI Population Health Program Population health seeks to identify and address variation in needs, care experiences, intervention efficacy, and outcomes for a defined group. In health systems, closing gaps often require collective actions of complex interdependent medical and social care systems in communities. The CTSI co-developed a Population Health Program with the local health department
- Image
Image CreditUCLA Clinical and Translational Science Institute (CTSI)OrganizationCaptionUCLA Clinical and Translational Science Institute (CTSI)UCLA Clinical and Translational Science Institute
The mission of the UCLA CTSI is to produce and implement innovations that impact the greatest health needs of Los Angeles and the nation. Our vision is to catalyze research that translates discoveries into tangible improvements in health care, disease prevention, and health in our community.
